Anbio Biotechnology (NASDAQ:NNNN) Hits New 52-Week Low – Time to Sell?

Shares of Anbio Biotechnology (NASDAQ:NNNN) reached a new 52-week low on Saturday . The company traded as low as $8.30 and last traded at $9.39, with a volume of 56447 shares. The stock had previously closed at $11.15.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Anbio Biotechnology from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, May 14th. One analyst has rated the stock with a Hold rating, According to MarketBeat.com, Anbio Biotechnology presently has a consensus rating of “Hold”.

Anbio Biotechnology Trading Down 15.8%

The stock’s fifty day moving average is $21.81.

Anbio Biotechnology (NASDAQ:NNNN) last released its earnings results on Tuesday, April 7th. The company reported $0.03 EPS for the quarter.

Anbio Biotechnology Company Profile

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.